ea0084ps3-12-108 | Graves’ Disease 2 and Orbitopathy | ETA2022
Zaletel Tjaša
, Rot Živa
, Krkovic Danijela
, Gaberscek Simona
, Zaletel Katja
Introduction: Radioiodine (I-131) therapy is an effective treatment for thyroid autonomy but may induce GravesÂ’ disease (GD) but in up to 5% of patients. GD is characterised by antibodies against TSH receptor (TSHRAb). We set out to evaluate the incidence and risk factors of I-131-induced GD in patients with thyroid autonomy treated with I-131.Methods: We retrospectively reviewed patients with solitary toxic adenoma or toxic nodular goiter who were ...